IQVIA™ Pharma Deals: PharmaDeals Review: Table of Contents

<< Previous Issue

Oct 2022 (Vol: 2022, Issue: 10)

Next Issue >>

Section: Licensing
Sanofi Collaborates with Scribe Therapeutics in CRISPR Cell Therapy Deal Published: 3 Oct-2022
By: Lucy Haggerty
Abstract Fulltext:
Puma Biotechnology Enters into Licensing Agreement with Takeda for Alisertib Published: 6 Oct-2022
By: Ashish Tripathi
Abstract Fulltext:
Seagen Signs Collaboration and License Agreement with Zai Lab for Tivdak® Published: 6 Oct-2022
By: Ayush Saxena
Abstract Fulltext:
Seagen Enters into License Agreement with Lava Therapeutics for LAVA-1223 Published: 7 Oct-2022
By: Ashish Tripathi
Abstract Fulltext:
Bristol Myers Squibb Signs Protein Degradation and Cell Therapy Technology Deals Published: 8 Oct-2022
By: Lucy Haggerty
Abstract Fulltext:
Jazz Pharmaceuticals Enters into License Agreement with Zymeworks for Zanidatamab Published: 26 Oct-2022
By: Ayush Saxena
Abstract Fulltext:
Section: Mergers & Acquisitions
AstraZeneca to Acquire LogicBio for US$68.2 M Published: 20 Oct-2022
By: Ashish Tripathi
Abstract Fulltext:
Incyte to Acquire Villaris Therapeutics for US$1.43 B Published: 26 Oct-2022
By: Amit Kaushik
Abstract Fulltext:
Section: Opinion & Analysis
IQVIA Pharma Deals Half-Year Review of 2022 Published: 14 Oct-2022
By: Heather Cartwright, Taskin Ahmed & Lucy Haggerty
Abstract Fulltext:
Section: Research & Development
Abpro Signs US$1.75 B Collaboration Deal with Celltrion Published: 14 Oct-2022
By: Amit Kaushik
Abstract Fulltext:
Bayer’s Vividion Signs US$930 M Cancer Collaboration with Tavros Therapeutics Published: 15 Oct-2022
By: Lucy Haggerty
Abstract Fulltext:
Gilead Signs US$1.7 B Deal with MacroGenics for Bispecific Antibodies Published: 20 Oct-2022
By: Lucy Haggerty
Abstract Fulltext:
Surrozen Collaborates with Boehringer Ingelheim to Develop SZN-413 for Retinal Disease Published: 21 Oct-2022
By: Ashish Tripathi
Abstract Fulltext:

Login

Username:

Password:

Keep me logged in